

HY-173116 · 50 mg
MedChemExpress · Cat: HY-173116
Reach 3+ verified distributors
Manufacturer product page
medchemexpress.com/dota-xyimsr-01.htmlDescription
DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of 177Lu Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram % ID/g , and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide HY-17364 can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy.







